China Pharma Holdings, Inc. Comments on Unusual Market Activity

Rhea-AI Summary

China Pharma Holdings (NYSE American: CPHI) reported that the NYSE American contacted the company on July 21, 2026 regarding unusual trading activity in its common stock. The company stated it is not aware of any material corporate developments explaining this volatility and urged investors to rely on its SEC filings and official press releases.

News Market Reaction – CPHI

-78.89% 5.2x vol

171 alerts

-78.89% Session close to close

+1386.0% Peak Tracked

-3.2% Trough Tracked

$44.57M Market Cap

5.2x Rel. Volume

In the Jul 22 session, CPHI declined 78.89%, reflecting a significant negative market reaction. Argus tracked a peak move of +1386.0% during that session. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 171 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 5.2x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -78.9% in the session following this news. A prior CPHI unusual-activity statement...

Analysis

The stock dropped -78.9% in the session following this news. A prior CPHI unusual-activity statement was followed by a 24.45% 24-hour move. That comparison informs the downside scenario, while current short positioning was low and did not indicate elevated short-interest risk.

Key Figures

Unusual activity date: July 21, 2026 NYSE American provision: Section 401(d)

2 metrics

Unusual activity date July 21, 2026 Date of unusual market activity

NYSE American provision Section 401(d) NYSE American Company Guide

Historical Context

2 past events · Latest: Jul 15 (Neutral)

Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	Unusual activity statement	Neutral	+78.9%	Company said it knew of no material information explaining unusual trading activity.
May 14	Unusual activity statement	Neutral	+24.4%	Company said it knew of no undisclosed developments explaining unusual trading activity.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Comparable unusual-activity statements were followed by positive 24-hour price reactions of 78.92% and 24.45%, indicating a recurring divergence between neutral disclosures and subsequent trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it issued this statement under Section 401(d) of the NYSE American Company Guide that it was not aware of any material corporate developments that would explain the recent market activity. Shareholders and prospective investors are cautioned to exercise care when evaluating the Company's securities in light of the recent volatility and to rely only on information contained in the Company's filings with the U.S. Securities and Exchange Commission and the Company's press releases.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company's beliefs, plans, and expectations, are forward-looking statements. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-comments-on-unusual-market-activity-302831292.html

SOURCE China Pharma Holdings, Inc.

FAQ

Why did China Pharma Holdings (CPHI) issue a statement on unusual market activity on July 21, 2026?

China Pharma issued the statement after NYSE American contacted the company about unusual trading in its stock. According to China Pharma, it responded under Section 401(d) of the NYSE American Company Guide to address investor concerns and clarify its awareness of corporate developments.

Is China Pharma Holdings (CPHI) aware of any material corporate developments behind the recent stock volatility?

According to China Pharma, the company is not aware of any material corporate developments that would explain the recent unusual market activity. It emphasized that there are no disclosed events it believes would account for the observed trading volatility in its common stock.

What did NYSE American ask China Pharma Holdings (CPHI) regarding its stock activity?

NYSE American contacted China Pharma in line with its usual practice when it observes unusual trading activity. According to China Pharma, the exchange’s inquiry prompted the company to state whether it was aware of any material corporate developments that could explain the stock’s recent volatility.

How should investors evaluate China Pharma Holdings (CPHI) during the recent stock volatility?

China Pharma cautioned shareholders and prospective investors to exercise care when evaluating its securities amid recent volatility. According to China Pharma, investors should rely only on information contained in its U.S. Securities and Exchange Commission filings and its official press releases when making decisions.

What guidance did China Pharma Holdings (CPHI) give about information sources for its stock?

China Pharma advised investors to rely solely on its filings with the U.S. Securities and Exchange Commission and its own press releases. According to China Pharma, this guidance is especially important in light of the recent volatility and any speculation in the market about its shares.